KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Revenue (2016 - 2025)

Historic Revenue for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $231.1 million.

  • Emergent BioSolutions' Revenue fell 2134.1% to $231.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $788.9 million, marking a year-over-year decrease of 1432.45%. This contributed to the annual value of $1.0 billion for FY2024, which is 54.32% down from last year.
  • Emergent BioSolutions' Revenue amounted to $231.1 million in Q3 2025, which was down 2134.1% from $140.9 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Revenue high stood at $732.9 million for Q4 2021, and its period low was $50.0 million during Q2 2024.
  • Its 5-year average for Revenue is $282.8 million, with a median of $276.6 million in 2023.
  • Its Revenue has fluctuated over the past 5 years, first plummeted by 8520.27% in 2024, then soared by 18180.0% in 2025.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Revenue stood at $732.9 million in 2021, then tumbled by 54.95% to $330.2 million in 2022, then dropped by 16.23% to $276.6 million in 2023, then dropped by 29.61% to $194.7 million in 2024, then increased by 18.7% to $231.1 million in 2025.
  • Its Revenue was $231.1 million in Q3 2025, compared to $140.9 million in Q2 2025 and $222.2 million in Q1 2025.